Non-small cell lung cancer (NSCLC) is known for high relapse rates despite resection in
early stages. Here, we present the results of a phase I clinical trial in which a dendritic cell …

Purpose Therapeutic outcomes of definitively treated non–small-cell lung cancer (NSCLC)
are unacceptably poor. A wealth of preclinical information, and a modest amount of clinical …

Background Overall therapeutic outcomes of advanced non-small-cell lung cancer (NSCLC)
are poor. The dendritic cell (DC) immunotherapy has been developed as a new strategy for …

Non-small-cell lung cancer (NSCLC) remains one of the leading causes of death worldwide.
While NSCLCs possess antigens that can potentially elicit T cell responses, defective tumor …

Only a handful of NSCLC patients have been included in dendritic cell (DC) vaccine clinical
trials. We had previously reported a series of 16 individuals with stages IA–IIIB NSCLC who …

Neoantigens are considered to be ultimate target of tumor immunotherapy due to their high
tumor specificity and immunogenicity. Dendritic cell (DCs) vaccines based on neoantigens …

Abstract Objective The J-SICT DC Vaccine Study Group provides dendritic cell (DC)
vaccines for compassionate use under unified cell production and patient treatment …

Background: We evaluated the clinical and immunological effects of dendritic cell (DC)
vaccination of patients with NSCLC. Autologous DCs were pulsed with a MAGE containing …

Immunotherapies can treat many cancers, including difficult-to-treat cases such as lung
cancer. Due to its tolerability, long-lasting therapeutic responses, and efficacy in a wide …

PURPOSE: Dendritic cell (DC)-based vaccines have been expected to serve as new
therapeutic approaches for advanced non-small cell lung cancers (NSCLCs); however, their …